Overview: Sepsis 16S 18S rRNA Sequencing TestIntroduction: The Sepsis 16S 18S rRNA Sequencing Test identifies pathogens via rRNA to diagnose sepsis, causing shock or fever. Following 2023 IDSA guidelines, it uses sequencing for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in bacteriology for patients with suspected sepsis.
Other Names: Sepsis rRNA Assay, Pathogen Sequencing Test.
FDA Status: Laboratory-developed test (LDT), meeting bacteriology standards for diagnostic accuracy.
Historical Milestone: rRNA sequencing for sepsis began in the 2000s with molecular diagnostics. Sequencing methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Identifies pathogens via 16S and 18S rRNA to diagnose sepsis, guides treatment, and evaluates patients with shock or fever.
Test Parameters: 1. Pathogen rRNA Detection
Pretest Condition: No fasting required. Collect whole blood, plasma, CSF, or saliva. Report history of shock, fever, or sepsis symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document shock, fever, or history of infections. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, sepsis implications, and risks of sample collection.
Procedural Considerations: Uses 16S and 18S rRNA sequencing to identify bacterial and fungal pathogens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for sepsis diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Antibiotic use may reduce sensitivity.
Clinical Significance: Positive rRNA detection identifies sepsis pathogens, guiding targeted antibiotic therapy. Negative results may require blood cultures.
Specialist Consultation: Consult an infectious disease specialist or critical care physician for result interpretation and treatment planning.
Additional Supporting Tests: Blood cultures, procalcitonin, or lactate levels to confirm sepsis diagnosis.
Test Limitations: Limited to detectable pathogens; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Sepsis Guidelines, 2023; Clinical Infectious Diseases, Pfaller MA, 2022.
